TransIT-VirusGEN® SELECT Transfection Reagent, Mirus Bio

Supplier: Mirus Bio
MIR6730 MIR6735
76470-370EA 42235.71 USD
76470-370 76333-948
TransIT-VirusGEN® SELECT Transfection Reagent, Mirus Bio
Transfection Reagents
Large scale virus production for preclinical and early phase clinical trials.

  • Efficient DNA delivery for large-scale production of high-titer virus vectors
  • Qualityt ested for performance, identity, sterility, endotoxin and mycoplasma
  • Reliabile with exceptional lot-to-lot consistency
  • Flexibilite with compatible with different virus production platforms and repeat filtration
  • Animal origin free, a fully synthetic transfection reagent formulation

Efficient, high titer and large-scale virus vector manufacturing processes are necessary for production of virus vectors such as lentivirus and adeno-associated virus (AAV) for gene- and cell-based therapies. Additionally, raw or ancillary materials used for virus vector manufacturing must be carefully selected as part of a risk-based approach for the development of therapeutics. The TransIT-VirusGEN® SELECT transfection reagent addresses both needs by providing robust titers for lentivirus and AAV production and comprehensive quality documentation for researchers developing biotherapeutics for immunotherapy.

TransIT-VirusGEN® SELECT is identical in formulation to the TransIT-VirusGEN® transfection reagent, which was developed by screening lipid and polymer libraries to identify a reagent formulation that enhances delivery of virus packaging and transfer vectors to HEK 293 cells. Using a functional titer read-out, Mirus scientists identified this novel and defined transfection formulation that enables high titer lentivirus and AAV production in both adherent, serum-containing cultures, as well as serum free suspension HEK 293-derived cell types.

The streamlined virus generation workflows and culture format versatility make TransIT-VirusGEN® an ideal reagent for scientists utilizing a variety of virus platforms. With TransIT-VirusGEN® SELECT, researchers can expect the same reliable, scalable, and flexible performance of the TransIT-VirusGEN® transfection Reagent as they progress from discovery and development to clinical trials.

In addition to the Quality Control testing established for TransIT-VirusGEN® Transfection Reagent, the TransIT-VirusGEN® SELECT transfection reagent is further qualified with sterility, identity, mycoplasma and endotoxin assays per relevant USP guidelines.

Certificaciones: Certificate of Origin: No Animal Derived Components.

Información para pedidos: TransIT-VirusGEN® SELECT Transfection Reagent is available as a 30 ml dispense.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR